These findings warrant further evaluation of p-PAK1 as a predictive biomarker for sunitinib response and resistance in RCC treatment and establish the evolving paradigm of using PAK1-targeted agents to assist antiangiogenic therapies. This evidence concerns the gene PAK1 and renal cell carcinoma.